{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T12:03:02Z","timestamp":1777896182786,"version":"3.51.4"},"reference-count":82,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"European Hematology AssociationEuropean Hematology Association"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.blre.2019.03.003","type":"journal-article","created":{"date-parts":[[2019,3,14]],"date-time":"2019-03-14T06:18:26Z","timestamp":1552544306000},"page":"51-58","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"special_numbering":"C","title":["Hypertension in hematologic malignancies and hematopoietic cell transplantation: An emerging issue with the introduction of novel treatments"],"prefix":"10.1016","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8883-8208","authenticated-orcid":false,"given":"Eleni","family":"Gavriilaki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugenia","family":"Gkaliagkousi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Savas","family":"Grigoriadis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Panagiota","family":"Anyfanti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stella","family":"Douma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Achilles","family":"Anagnostopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.blre.2019.03.003_bb0005","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1001\/jama.2018.16579","article-title":"Treatment of hypertension: addressing a global health problem","volume":"320","author":"Qamar","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.blre.2019.03.003_bb0010","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/S0140-6736(10)62036-3","article-title":"National, regional, and global trends in systolic blood pressure since 1980: systematic analysis of health examination surveys and epidemiological studies with 786 country-years and 5.4 million participants","volume":"377","author":"Danaei","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.blre.2019.03.003_bb0015","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1097\/RHU.0b013e31827846b1","article-title":"Cardiovascular risk in rheumatoid arthritis: pathogenesis, diagnosis, and management","volume":"18","author":"Gkaliagkousi","year":"2012","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.blre.2019.03.003_bb0020","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.thromres.2016.02.001","article-title":"Understanding cardiovascular risk in hemophilia: A step towards prevention and management","volume":"140","author":"Sousos","year":"2016","journal-title":"Thromb Res"},{"key":"10.1016\/j.blre.2019.03.003_bb0025","first-page":"263","article-title":"Hypertension in cancer patients","volume":"38","author":"Mouhayar","year":"2011","journal-title":"Tex Heart Inst J\/Tex Heart Inst St Luke's Episcopal Hosp, Tex Child Hosp"},{"key":"10.1016\/j.blre.2019.03.003_bb0030","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.bbmt.2014.02.012","article-title":"Late cardiovascular complications after hematopoietic cell transplantation","volume":"20","author":"Chow","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2019.03.003_bb0035","doi-asserted-by":"crossref","first-page":"3784","DOI":"10.1182\/blood-2007-03-082933","article-title":"Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the bone marrow transplant survivor study","volume":"110","author":"Bhatia","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.03.003_bb0040","doi-asserted-by":"crossref","first-page":"e91","DOI":"10.1016\/S2352-3026(15)00028-9","article-title":"One million haemopoietic stem-cell transplants: a retrospective observational study","volume":"2","author":"Gratwohl","year":"2015","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.blre.2019.03.003_bb0045","series-title":"New Insights in Hematopoietic Cell Transplantation: Research Signpost","article-title":"Hematopoietic stem cell transplantation: Historical perspectives","author":"Sakellari","year":"2010"},{"key":"10.1016\/j.blre.2019.03.003_bb0050","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1097\/HJH.0b013e32834c465d","article-title":"Drug-related hypertension and resistance to antihypertensive treatment: a call for action","volume":"29","author":"Rossi","year":"2011","journal-title":"J Hypertens"},{"key":"10.1016\/j.blre.2019.03.003_bb0055","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.beem.2006.07.001","article-title":"Cortisol metabolism in hypertension","volume":"20","author":"Hammer","year":"2006","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1016\/j.blre.2019.03.003_bb0060","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1097\/TP.0000000000001243","article-title":"Calcineurin inhibitor nephrotoxicity through the Lens of longitudinal histology: comparison of cyclosporine and tacrolimus eras","volume":"100","author":"Nankivell","year":"2016","journal-title":"Transplantation"},{"key":"10.1016\/j.blre.2019.03.003_bb0065","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.blre.2014.11.001","article-title":"A new paradigm: diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injury","volume":"29","author":"Jodele","year":"2015","journal-title":"Blood Rev"},{"key":"10.1016\/j.blre.2019.03.003_bb0070","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1182\/blood-2014-11-611335","article-title":"Drug-induced thrombotic microangiopathy: a systematic review of published reports","volume":"125","author":"Al-Nouri","year":"2015","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.blre.2019.03.003_bb0075","doi-asserted-by":"crossref","first-page":"E241","DOI":"10.1002\/ajh.25208","article-title":"Drug-induced thrombotic microangiopathy: an updated systematic review, 2014\u20132018","volume":"93","author":"Saleem","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2019.03.003_bb0080","doi-asserted-by":"crossref","first-page":"345","DOI":"10.2215\/CJN.02070508","article-title":"Renal thrombotic microangiopathy after hematopoietic cell transplant: role of GVHD in pathogenesis","volume":"4","author":"Changsirikulchai","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.blre.2019.03.003_bb0085","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1002\/ajh.20648","article-title":"Risk factor analysis for thrombotic microangiopathy after reduced-intensity or myeloablative allogeneic hematopoietic stem cell transplantation","volume":"81","author":"Nakamae","year":"2006","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2019.03.003_bb0090","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/bmt.2009.230","article-title":"Comparison of thrombotic microangiopathy after allogeneic hematopoietic cell transplantation with high-dose or nonmyeloablative conditioning","volume":"45","author":"Willems","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.blre.2019.03.003_bb0095","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1097\/01.tp.0000230373.82376.46","article-title":"Risk factors and severe outcome in thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation","volume":"82","author":"Uderzo","year":"2006","journal-title":"Transplantation."},{"key":"10.1016\/j.blre.2019.03.003_bb0100","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.bbmt.2005.06.001","article-title":"Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation","volume":"11","author":"Ho","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2019.03.003_bb0105","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1182\/blood-2014-03-564997","article-title":"Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a study in children and young adults","volume":"124","author":"Jodele","year":"2014","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.blre.2019.03.003_bb0110","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.13371","article-title":"Transplant-associated thrombotic microangiopathy: incidence, prognostic factors, morbidity and mortality in allogeneic hematopoietic cell transplantation","volume":"32","author":"Gavriilaki","year":"2018","journal-title":"Clin Transpl"},{"key":"10.1016\/j.blre.2019.03.003_bb0115","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1038\/bmt.2017.39","article-title":"Transplant-associated thrombotic microangiopathy: opening Pandora's box","volume":"52","author":"Gavriilaki","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.blre.2019.03.003_bb0120","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1182\/blood-2011-02-321315","article-title":"Small vessels, big trouble in the kidneys and beyond: hematopoietic stem cell transplantation-associated thrombotic microangiopathy","volume":"118","author":"Laskin","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.03.003_bb0125","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1182\/blood-2013-05-501445","article-title":"Abnormalities in the alternative pathway of complement in children with hematopoietic stem cell transplant-associated thrombotic microangiopathy","volume":"122","author":"Jodele","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.03.003_bb0130","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1182\/blood-2015-08-663435","article-title":"The genetic fingerprint of susceptibility for transplant-associated thrombotic microangiopathy","volume":"127","author":"Jodele","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.03.003_bb0135","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1016\/j.bbmt.2017.07.018","article-title":"Unraveling the genetics of transplant-associated thrombotic Microangiopathy: lessons to be learned","volume":"23","author":"Gavriilaki","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2019.03.003_bb0140","series-title":"Complement-Related Genetic Variants in Adult Allogeneic Hematopoietic Cell Transplant Recipients with Transplant-Associated Thrombotic Microangiopathy","author":"Gavriilaki","year":"2018"},{"key":"10.1016\/j.blre.2019.03.003_bb0145","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1182\/bloodadvances.2017008250","article-title":"In vitro evidence of complement activation in transplantation-associated thrombotic microangiopathy","volume":"1","author":"Rotz","year":"2017","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.blre.2019.03.003_bb0150","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.amjmed.2018.08.011","article-title":"Atypical hemolytic uremic syndrome: beyond hemolysis and uremia","volume":"132","author":"Tsai","year":"2018","journal-title":"Am J Med"},{"key":"10.1016\/j.blre.2019.03.003_bb0155","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.bbmt.2010.02.006","article-title":"Chronic kidney disease, thrombotic microangiopathy, and hypertension following T cell-depleted hematopoietic stem cell transplantation","volume":"16","author":"Glezerman","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2019.03.003_bb0160","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJM199602223340803","article-title":"A reversible posterior leukoencephalopathy syndrome","volume":"334","author":"Hinchey","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2019.03.003_bb0165","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1016\/j.bbmt.2015.07.023","article-title":"Clinical utility of computed tomography and magnetic resonance imaging for diagnosis of posterior reversible encephalopathy syndrome after stem cell transplantation in children and adolescents","volume":"21","author":"Dandoy","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2019.03.003_bb0170","article-title":"The 44th annual meeting of the European Society for Blood and Marrow Transplantation: physicians poster sessions","author":"Sakellari","year":"2018","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.blre.2019.03.003_bb0175","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1007\/s00415-016-8377-8","article-title":"Posterior reversible encephalopathy syndrome","volume":"264","author":"Fischer","year":"2017","journal-title":"J Neurol"},{"key":"10.1016\/j.blre.2019.03.003_bb0180","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.3174\/ajnr.A0929","article-title":"Posterior reversible encephalopathy syndrome, part 2: controversies surrounding pathophysiology of vasogenic edema","volume":"29","author":"Bartynski","year":"2008","journal-title":"AJNR Am J Neuroradiol"},{"key":"10.1016\/j.blre.2019.03.003_bb0185","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.mehy.2014.02.022","article-title":"Posterior reversible encephalopathy syndrome: the endothelial hypotheses","volume":"82","author":"Marra","year":"2014","journal-title":"Med Hypotheses"},{"key":"10.1016\/j.blre.2019.03.003_bb0190","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/S1474-4422(15)00111-8","article-title":"Posterior reversible encephalopathy syndrome: clinical and radiological manifestations, pathophysiology, and outstanding questions","volume":"14","author":"Fugate","year":"2015","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.blre.2019.03.003_bb0195","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1097\/HJH.0000000000001940","volume":"36","author":"Williams","year":"2018","journal-title":"J Hypertens"},{"key":"10.1016\/j.blre.2019.03.003_bb0200","doi-asserted-by":"crossref","first-page":"3463","DOI":"10.1182\/blood-2006-10-054080","article-title":"Premature cardiovascular disease after allogeneic hematopoietic stem-cell transplantation","volume":"110","author":"Tichelli","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.03.003_bb0205","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.2165\/0002018-200831120-00005","article-title":"Long-term consequences of drugs on the paediatric cardiovascular system","volume":"31","author":"Hausner","year":"2008","journal-title":"Drug Saf"},{"key":"10.1016\/j.blre.2019.03.003_bb0210","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1038\/bmt.2013.55","article-title":"GVHD-associated chronic kidney disease after allogeneic haematopoietic cell transplantation","volume":"48","author":"Sakellari","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.blre.2019.03.003_bb0215","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1002\/pbc.21695","article-title":"Renal late effects in patients treated for cancer in childhood: a report from the children's oncology group","volume":"51","author":"Jones","year":"2008","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.blre.2019.03.003_bb0220","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1007\/s00467-017-3771-8","article-title":"Factors associated with cardiovascular target organ damage in children after renal transplantation","volume":"32","author":"Borchert-Morlins","year":"2017","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.blre.2019.03.003_bb0225","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1007\/s12012-015-9324-0","article-title":"Endothelial function in patients with hematologic malignancies undergoing high-dose chemotherapy followed by hematopoietic stem cell transplantation","volume":"16","author":"Poreba","year":"2016","journal-title":"Cardiovasc Toxicol"},{"key":"10.1016\/j.blre.2019.03.003_bb0230","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1182\/blood-2006-05-022335","article-title":"Diabetes, hypertension, and cardiovascular events in survivors of hematopoietic cell transplantation: a report from the bone marrow transplantation survivor study","volume":"109","author":"Baker","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.03.003_bb0235","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.3324\/haematol.12949","article-title":"Late cardiovascular events after allogeneic hematopoietic stem cell transplantation: a retrospective multicenter study of the late effects working party of the European group for blood and marrow transplantation","volume":"93","author":"Tichelli","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2019.03.003_bb0240","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1182\/bloodadvances.2018019117","article-title":"Prediction of cardiovascular disease among hematopoietic cell transplantation survivors","volume":"2","author":"Armenian","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2019.03.003_bb0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbmt.2012.01.003","volume":"18","author":"Pulsipher","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2019.03.003_bb0250","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/bmt.2016.203","article-title":"Metabolic syndrome and cardiovascular disease following hematopoietic cell transplantation: screening and preventive practice recommendations from CIBMTR and EBMT","volume":"52","author":"DeFilipp","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.blre.2019.03.003_bb0255","series-title":"Pediatric Hypertension","article-title":"Hypertension in oncology and stem-cell transplant patients","author":"Laskin","year":"2016"},{"key":"10.1016\/j.blre.2019.03.003_bb0260","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1001\/jamacardio.2018.0005","article-title":"The 2017 American college of cardiology\/american heart association clinical practice guideline for high blood pressure in adults","volume":"3","author":"Whelton","year":"2018","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.blre.2019.03.003_bb0265","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s11906-015-0596-3","article-title":"Clinical significance of endothelial dysfunction in essential hypertension","volume":"17","author":"Gkaliagkousi","year":"2015","journal-title":"Curr Hypertens Rep"},{"key":"10.1016\/j.blre.2019.03.003_bb0270","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1016\/j.ijrobp.2007.08.041","article-title":"Captopril to mitigate chronic renal failure after hematopoietic stem cell transplantation: a randomized controlled trial","volume":"70","author":"Cohen","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.blre.2019.03.003_bb0275","doi-asserted-by":"crossref","first-page":"311","DOI":"10.2174\/1568009617666161121141607","article-title":"Chemotherapy and cardiotoxicity in hematologic malignancies","volume":"17","author":"Stellitano","year":"2017","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1016\/j.blre.2019.03.003_bb0280","first-page":"59","article-title":"Chemotherapy-induced cardiotoxicity","volume":"8","author":"Florescu","year":"2013","journal-title":"Maedica"},{"key":"10.1016\/j.blre.2019.03.003_bb0285","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.2174\/13895575113139990061","article-title":"Novel anticancer agents and targets: recent advances and future perspectives","volume":"13","author":"Barot","year":"2013","journal-title":"Mini Rev Med Chem"},{"key":"10.1016\/j.blre.2019.03.003_bb0290","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1172\/JCI9083","article-title":"Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia","volume":"105","author":"Druker","year":"2000","journal-title":"J Clin Invest"},{"key":"10.1016\/j.blre.2019.03.003_bb0295","article-title":"Imatinib in chronic myeloid leukemia: an overview","volume":"6","author":"Sacha","year":"2014","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"10.1016\/j.blre.2019.03.003_bb0300","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.clml.2015.03.006","article-title":"Use of second- and third-generation tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia: an evolving treatment paradigm","volume":"15","author":"Jabbour","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.blre.2019.03.003_bb0305","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s11936-017-0524-8","article-title":"Cardiovascular complications of targeted therapies for chronic myeloid leukemia","volume":"19","author":"Damrongwatanasuk","year":"2017","journal-title":"Curr Treat Options Cardiovasc Med"},{"key":"10.1016\/j.blre.2019.03.003_bb0310","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1038\/ki.2011.288","article-title":"Proteinuria and hypertension with tyrosine kinase inhibitors","volume":"80","author":"Kandula","year":"2011","journal-title":"Kidney Int"},{"key":"10.1016\/j.blre.2019.03.003_bb0315","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s11912-018-0708-8","article-title":"Tyrosine kinase inhibitor-induced hypertension","volume":"20","author":"Agarwal","year":"2018","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.blre.2019.03.003_bb0320","doi-asserted-by":"crossref","first-page":"6227","DOI":"10.2147\/OTT.S170138","article-title":"Mechanisms, monitoring, and management of tyrosine kinase inhibitors-associated cardiovascular toxicities","volume":"11","author":"Chaar","year":"2018","journal-title":"OncoTargets Ther"},{"key":"10.1016\/j.blre.2019.03.003_bb0325","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.clml.2016.11.009","article-title":"Incidence and risk of cardiac events in patients with previously treated multiple myeloma versus matched patients without multiple myeloma: an observational, retrospective, cohort study","volume":"17","author":"Kistler","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.blre.2019.03.003_bb0330","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s11523-017-0504-7","article-title":"Ixazomib: A review in relapsed and\/or refractory multiple myeloma","volume":"12","author":"Al-Salama","year":"2017","journal-title":"Target Oncol"},{"key":"10.1016\/j.blre.2019.03.003_bb0335","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/S1470-2045(14)71125-8","article-title":"Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1\/2 study","volume":"15","author":"Kumar","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.blre.2019.03.003_bb0340","first-page":"1","article-title":"Cardiotoxicity associated with carfilzomib: systematic review and meta-analysis","author":"Shah","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2019.03.003_bb0345","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.4519","article-title":"Carfilzomib-associated cardiovascular adverse events: A systematic review and meta-analysis","volume":"4","author":"Waxman","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.blre.2019.03.003_bb0350","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/leu.2016.186","article-title":"Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study","volume":"31","author":"Moreau","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2019.03.003_bb0355","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1182\/bloodadvances.2017015545","article-title":"Analysis of carfilzomib cardiovascular safety profile across relapsed and\/or refractory multiple myeloma clinical trials","volume":"2","author":"Chari","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2019.03.003_bb0360","first-page":"1","article-title":"Phase 1 trial of ibrutinib and carfilzomib combination therapy for relapsed or relapsed and refractory multiple myeloma","author":"Chari","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2019.03.003_bb0365","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1038\/s41375-018-0040-1","article-title":"Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European myeloma network","volume":"32","author":"Ludwig","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2019.03.003_bb0370","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2014.93","article-title":"Cardiac complications in relapsed and refractory multiple myeloma patients treated with carfilzomib","volume":"5","author":"Atrash","year":"2015","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.blre.2019.03.003_bb0375","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s11906-014-0447-7","article-title":"Hypertension as a risk factor for heart failure","volume":"16","author":"Kannan","year":"2014","journal-title":"Curr Hypertens Rep"},{"key":"10.1016\/j.blre.2019.03.003_bb0380","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/S0140-6736(12)60605-9","article-title":"Non-Hodgkin lymphoma","volume":"380","author":"Shankland","year":"2012","journal-title":"Lancet."},{"key":"10.1016\/j.blre.2019.03.003_bb0385","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.clml.2018.06.016","article-title":"Safety analysis of four randomized controlled studies of Ibrutinib in patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma or mantle cell lymphoma","volume":"18","author":"O'Brien","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.blre.2019.03.003_bb0390","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s13045-018-0626-0","article-title":"Predictors of atrial fibrillation in ibrutinib-treated CLL patients: a prospective study","volume":"11","author":"Reda","year":"2018","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.blre.2019.03.003_bb0395","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1080\/10428194.2016.1257795","article-title":"Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL)","volume":"58","author":"Shanafelt","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2019.03.003_bb0400","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1093\/annonc\/mdx289","article-title":"Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma","volume":"28","author":"Dreyling","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.blre.2019.03.003_bb0405","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18081736","article-title":"Hypertension caused by Lenvatinib and Everolimus in the treatment of metastatic renal cell carcinoma","volume":"18","author":"Bendtsen","year":"2017","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.blre.2019.03.003_bb0410","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.2147\/OTT.S142264","article-title":"Spotlight on copanlisib and its potential in the treatment of relapsed\/refractory follicular lymphoma: evidence to date","volume":"11","author":"Mensah","year":"2018","journal-title":"OncoTargets Ther"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X18301206?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X18301206?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T20:22:24Z","timestamp":1759436544000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X18301206"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":82,"alternative-id":["S0268960X18301206"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2019.03.003","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hypertension in hematologic malignancies and hematopoietic cell transplantation: An emerging issue with the introduction of novel treatments","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2019.03.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}